| 07:30 - 08:15 |
: |
Morning Session 1: Laboratory Diagnosis of Viral Hepatitis
| Venue: |
401 |
| 07:30 - 08:15 |
Jun Cheng, Beijing
|
| 07:30 - 08:15 |
Chun-Jen Liu, Taipei
|
|
| 07:30 - 08:15 |
: |
Morning Session 2: Animal Model for the Study of Liver Disease
| Venue: |
402 |
| 07:30 - 08:15 |
Qin Ning, Wuhan
|
| 07:30 - 08:15 |
Jian Wu, Sacramento
|
|
| 07:30 - 08:15 |
: |
Morning Session 3: Clinical Implications of the Recent Publications of Hepatitis B
| Venue: |
403 |
| 07:30 - 08:15 |
Eugene Schiff, Miami
|
| 07:30 - 08:15 |
Wan-Cheng Chow, Singapore
|
|
| 07:30 - 08:15 |
: |
Morning Session 4: Risk Factors for Hepatocellular Carcinoma
| Venue: |
405 |
| 07:30 - 08:15 |
Chien-Jen Chen, Taipei
|
| 07:30 - 08:15 |
Yoon Jun Kim, Seoul
|
|
| 07:30 - 08:15 |
: |
Morning Session 5: Endoscopic Management in Hepatology
| Venue: |
406 |
| 07:30 - 08:15 |
Shu-Tian Zhang, Beijing
|
| 07:30 - 08:15 |
Hsiu-Po Wang, Taipei
|
|
| 07:30 - 08:15 |
: |
Morning Session 6: Portal Hypertension
| Venue: |
407 |
| 07:30 - 08:15 |
Laurentius A. Lesmana, Jakarta
|
| 07:30 - 08:15 |
Jose D. Sollano, Manila
|
|
| 08:30 - 09:00 |
: |
State-of-the Art Lecture 2
| Venue: |
Auditorium |
| Moderator: |
Jian-Ren Gu, Shanghai
Lewis R. Roberts, Rochester |
| 08:30 - 09:00 |
Therapeutic Potential of Adipose Derived Stem Cells on Liver Disease
Takahiro Ochiya,Tokyo |
|
| 08:30 - 09:00 |
: |
Keynote Lecture 2
| Venue: |
Plenary Hall A |
| Moderator: |
Hui Zhuang, Beijing
Emmet B. Keeffe, Stanford |
| 08:30 - 09:00 |
Toward the Elimination and Eradication of Hepatitis B Virus Infection
Ding-Shinn Chen, Taipei |
|
| 09:00 - 09:30 |
: |
State-of-the Art Lecture 3
| Venue: |
Auditorium |
| Moderator: |
Fu-Chu He, Beijing
David A. Brenner, La Jolla |
| 09:00 - 09:30 |
Liver Tissue Engineering: Basic Research and their Translation into the Therapies of the Future
Hanry Yu, Singapore |
|
| 09:00 - 09:30 |
: |
Keynote Lecture 3
| Venue: |
Plenary Hall A |
| Moderator: |
Lai Wei, Beijing
Ed Gane, Auckland |
| 09:00 - 09:30 |
Recent Advances in Chronic Hepatitis C Therapy: From Virus to Host
Jia-Horng Kao, Taipei |
|
| 10:00 - 11:30 |
: |
Concurrent Session 7 : The World inside Hepatitis C
| Venue: |
Function Hall A |
| Moderator: |
Xue-Fan Bai, Xian
Jacob George, Westmead |
| 10:00 - 10:20 |
Hepatitis C Virus Tropism and Pathogenesis
Michael M.C. Lai, Taipei |
| 10:20 - 10:40 |
Viral Kinetics and Drug Resistance
Alan S. Perelson, Los Alamos |
| 10:40 - 11:00 |
Hepatitis C Virus JFH-1 Strain
Takaji Wakita, Tokyo |
| 11:00 - 11:20 |
The Association of Single nucleotide polymorphisms of Interleukin 28B and the Response to Pegylated Interferon-alfa with Ribavirin for HCV Infected Japanese Patients
Masashi Mizokami, Ichikawa |
| 11:20 - 11:30 |
Discussion: Direction for the Future Treatment
|
|
| 10:00 - 11:30 |
: |
Concurrent Session 8 : Cirrhosis and Portal Hypertension
| Venue: |
Function Hall B |
| Moderator: |
Gustav Paumgartner, Munich |
| 10:00 - 10:20 |
Pathology of Cirrhosis: Liver Dysfunction and Portal Hypertension
Ashish Kumar, New Delhi |
| 10:20 - 10:40 |
Prediction of Cirrhosis and Liver Biopsy
Darrell H.G. Crawford, Brisbane |
| 10:40 - 11:00 |
Management of Portal Hypertension: TIPS
Thomas Boyer, Tucson |
| 11:00 - 11:20 |
Adjuvant Therapy to Endoscopic Management of Variceal Bleeding
Shahab Abid, Karachi |
| 11:20 - 11:30 |
Discussion: Medical or Surgical Therapy
|
|
| 10:00 - 11:30 |
: |
Concurrent Session 9 : Diagnosis and Staging of Liver Cancer: Early Detection
| Venue: |
Function Hall C |
| Moderator: |
Xiao-Ping Chen, Wuhan
Osamu Yokosuka, Chiba |
| 10:00 - 10:20 |
Early Detection of HCC: Diagnosis and Treatment
Massimo Colombo, Milan |
| 10:20 - 10:40 |
Application of Surveillance Programs for HCC
Hubert E. Blum, Freiburg |
| 10:40 - 11:00 |
Diagnosis of Liver Cancer: Imaging Techniques
Byung Ihn Choi, Seoul |
| 11:00 - 11:20 |
Modern Diagnosis of HCC
Jorge A. Marrero, Ann Arbor |
| 11:20 - 11:30 |
Discussion: The Best Staging System
|
|
| 11:30 - 11:45 |
: |
Plenary Presentation 7
| Venue: |
Function Hall A |
| Moderator: |
Xue-Fan Bai, Xian
Jacob George, Westmead |
| 11:30 - 11:45 |
TLR7 Expression and Function is Decreased in HCV Infected Hepatoma Cells
Gyongyi Szabo |
|
| 11:30 - 11:45 |
: |
Plenary Presentation 8
| Venue: |
Function Hall B |
| Moderator: |
Gustav Paumgartner, Munich |
| 11:30 - 11:45 |
Wait-and-See Policy (Conservative Treatment) vs. Cholecystectomy after Endoscopic Sphincterotomy for Bile Duct Stones in Patients with co-existing Gallbladder Stones in Elderly and high Surgical Risk Patients: a Prospective Randomized Trial
Showkat Ali Zargar |
|
| 11:30 - 11:45 |
: |
Plenary Presentation 9
| Venue: |
Function Hall C |
| Moderator: |
Xiao-Ping Chen, Wuhan
Osamu Yokosuka, Chiba |
| 11:30 - 11:45 |
Angio-CT findings of 115 small hepatocellular carcinomas of 61 patients during follow- up of 659 patients with chronic liver disease.Clinical features of early cancers
Shozo Iwamoto |
|
| 13:30 - 18:30 |
: |
Cost Effectiveness of CHB Symposium - Consensus Parameter for Cost Effective Studies?
| Venue: |
Auditorium |
| Description: |
Objectives of Meeting: The over-arching objective of this workshop is to develop models the cost-effectiveness of various strategies for HBV treatment resistance. There are three goals. (i) to review current assumptions on natural history of chronic HBV infection. (ii) to determine appropriate treatment endpoints and long term efficacy of different treatment regimens. (iii) To develop Markov models for cost-effectiveness in different settings. |
| Chairperson: |
Rajen Koshy, Bethesda
Seng-Gee Lim, Singapore
Anna S.F. Lok, ann Arbor |
| 13:30 - 13:35 |
Introduction
|
| 13:35 - 13:50 |
Prevention of Nosocomial HBV Infection
Benjamin C. Cowie, Melbourne |
| 13:50 - 14:10 |
The Markov Model Cost Effectiveness Overview
Yock-Young Dan, Singapore |
| 14:10 - 14:30 |
Basic Princples of Health Economics and Markov Modeling - Application to Hepatitis B Treatment
John B. Wong, Boston |
| 14:30 - 15:00 |
Endpoints of Treatment
Teerha Piratvisuth, Hat Yai |
| 15:00 - 15:15 |
Break
|
| 15:15 - 15:45 |
Current Assumption o Natural History
Henry L.Y. Chan, Hong Kong |
| 15:45 - 16:00 |
Efficacy of Approved Therapies
Chun-Jen Liu, Taipei |
| 16:15 - 16:30 |
Break
|
| 16:30 - 18:30 |
Panel Discussion
|
|
| 14:00 - 15:30 |
: |
Concurrent Session 10: Clinical Updates for Hepatitis C
| Venue: |
Function Hall A |
| Moderator: |
Xiao-Guang Dou, Shenyang
Marilyn O. Arguillas, Manila |
| 14:00 - 14:20 |
Detection of Hepatitis C Virus Infection
Lai Wei, Beijing |
| 14:20 - 14:40 |
Treatment of Hepatitis C in Asia Pacific Region
Wan-Long Chuang, Kaohsiung |
| 14:40 - 15:00 |
Management of Non-responders
Peter Ferenci, Vienna |
| 15:00 - 15:20 |
HALT-C Trial and IDEAL Study – Retrospective Analysis of Two Large Multicenter Studies and their Role for Future Hepatitis C Therapies
Michael P. Manns, Hannover |
| 15:20 - 15:30 |
Discussion: The Role of the Investigational HCV Agents
|
|
| 14:00 - 15:30 |
: |
Concurrent Session 11: Complications of Cirrhosis
| Venue: |
Function Hall B |
| Moderator: |
Ji-Yao Wang, Shanghai
Yogesh K. Chawla, Chandigarh |
| 14:00 - 14:20 |
Minimal Hepatic Encephalopathy
Barjesh C. Sharma, New Delhi |
| 14:20 - 14:40 |
Prophylaxis of Spontaneous Bacterial Peritonitis (SBP)
Dong Jin Suh, Seoul |
| 14:40 - 15:00 |
Management of Refractory Ascites and Hepatorenal Syndrome
Anuchit Chutaputti, Bangkok |
| 15:00 - 15:20 |
Hepatopulomonary Syndrome: a Liver-induced Pulmonary Vascular Challenge
Roberto Rodríguez-Roisin, Barcelona |
| 15:20 - 15:30 |
Discussion: The Use of Antibiotics
|
|
| 14:00 - 15:30 |
: |
Concurrent Session 12: Surgical and Interventional Approach to Liver Cancer
| Venue: |
Function Hall C |
| Moderator: |
Min-Shan Chen, Guangzhou
Joseph W.Y. Lau, Hong Kong |
| 14:00 - 14:20 |
Multidisciplinary Approach to Liver Cancer: Early to Advanced Liver Cancer
Ronnie T.P. Poon, Hong Kong |
| 14:20 - 14:40 |
Advances in the Liver Cancer Surgery
Mitsuo Shimada, Tokushima |
| 14:40 - 15:00 |
Radiation Therapy for Liver Cancer: Current Status and Perspectives from Our Experience
Zhao-Chong Zeng, Shanghai |
| 15:00 - 15:20 |
Application of Intraoperative Ultrasonography
Guido Torzilli, Milan |
| 15:20 - 15:30 |
Discussion: The Role of Intra-Arterial Infusion Chemotherapy
|
|
| 15:30 - 15:45 |
: |
Plenary Presentation 10
| Venue: |
Function Hall A |
| Moderator: |
Xiao-Guang Dou, Shenyang
Marilyn O. Arguillas, Manila |
| 15:30 - 15:45 |
METABOLIC FACTORS HAVE NO INFLUENCE ON ACCURACY OF TRANSIENT ELASTOGRAPHY IN CHRONIC HEPATITIS B AND C
Ana Carolina Cardoso |
|
| 15:30 - 15:45 |
: |
Plenary Presentation 11
| Venue: |
Function Hall B |
| Moderator: |
Ji-Yao Wang, Shanghai
Yogesh K. Chawla, Chandigarh |
| 15:30 - 15:45 |
Natural history of asymptomatic and symptomatic portal biliopathy in patients with extra-hepatic portal vein obstruction (EHPVO)
Nitin Gupta |
|
| 15:30 - 15:45 |
: |
Plenary Presentation 12
| Venue: |
Function Hall C |
| Moderator: |
Min-Shan Chen, Guangzhou
Joseph W.Y. Lau, Hong Kong |
| 15:30 - 15:45 |
Radiological Characteristics of Hepatocellular Carcinoma with Better Survivals after Partial Hepatectomy
Kevin Ka Wan Chu |
|
| 16:15 - 18:15 |
: |
General Session 2: Updates and Decision Making in Hepatology - Liver Failure
| Venue: |
Plenary Hall A |
| Moderator: |
Yu-Ming Wang, Chongqing
George K.K. Lau, Hong Kong |
| 16:15 - 16:25 |
European Perspective with Case Presentation
Roger S. Williams, London |
| 16:25 - 16:55 |
Discussion
|
| 16:55 - 17:05 |
American Perspective with Case Presentation
Julie Polson, Denver |
| 17:05 - 17:35 |
Discussion
|
| 17:35 - 17:45 |
Asian Pacific Perspective with Case presentation
Shiv K. Sarin, New Delhi |
| 17:45 - 18:15 |
Discussion
|
|
| 16:15 - 18:15 |
: |
Free Paper Presentation 7: Hepatitis B (III)
| Venue: |
Meeting Room 401 |
| 16:15 - 16:25 |
FibroScan® Detecting Severity of Liver Disease Accurately in Chinese Patients with Chronic Hepatitis B
Yong-Peng Chen, Guangzhou |
| 16:25 - 16:35 |
A Clinical Scoring System to Predict Hepatocellular Carcinoma in Chronic Hepatitis B Carriers
Vincent Wong, Hong Kong |
| 16:35 - 16:45 |
HBV Subgenotype Distribution in Chinese Patients with Chronic HBV Infection-- a Hospital-based Analysis of 4,118 Cases
Dongping Xu, Beijing |
| 16:45 - 16:55 |
The Expression of miRNA in the Peripheral Blood Mononuclear Cells (PBMC) of the Hepatitis B Patients During Virus Clearance
Lin Wang, Shanghai |
| 16:55 - 17:05 |
Analysis of Dimensionless Virus Infection Model with Immune and Prediction for Long-term Therapy Effect
Yu Zheng, Beijing |
| 17:05 - 17:15 |
Modeling Dynamics of Acutely Infected Chimpanzees
Xiao Chen, Beijing |
| 17:15 - 17:25 |
Prevalence and Risk Factors Associated with HBV Transmission in Pakistani Population
Yasir Waheed, Islamabad |
| 17:25 - 17:35 |
Prospective Randomized Trial of Switching to Entecavir in Chronic Hepatitis B Patients with Suboptimal Virologic Response to Lamivudine: Interim Analysis at 48 Weeks
Sang Hoon Ahn, Seoul |
| 17:35 - 17:45 |
The Epidemiological and Economic Impact of Chronic Hepatitis B in Australia to 2017 and the Cost-effectiveness of Enhanced Treatment
James RG Butler, Canberra |
| 17:45 - 17:55 |
Effectiveness of Telbivudine as Add-on Therapy in a Population of Chronic Hepatitis Patients with Suboptimal Response to Tenofovir
Stephan Kaiser, Stuttgart |
| 17:55 - 18:05 |
Profile of HBV DNA in a Large Population of Chinese Chronic Hepatitis B Patients: Implications for Antiviral Theraphy
James Fung, Hong Kong |
| 18:05 - 18:15 |
Comparsion of ALT and HBV DNA Levels with Histological Lesions in Chronic Hepatitis B: Implications for Treatment Decision
Ana Carolina Cardoso, Clichy |
|
| 16:15 - 18:15 |
: |
Free Paper Presentation 8: Hepatitis B (IV)
| Venue: |
Meeting Room 402 |
| 16:15 - 16:25 |
A Multicenter Cohort Study of Telbivudine in HBeAg-positive Patients with Chronic Hepatitis B (an Interim Analysis)
Xiaoguang Dou, Shenyang |
| 16:25 - 16:35 |
Early vs Salvage Add-on Adefovir Therapy in Telbivudine-treated Patients Who do not Achieve Undetectable HBV DNA Levels at 6 Months
Hsien-Chung Yu, Kaohsiung |
| 16:35 - 16:45 |
Lamivudine-resistant Hepatitis B Patients may be Selected for Entecavir Monotherapy Based on their Pre-treatment Resistance Substitutions – a Four-Year Cohort Study
Guan-Huei Lee, Singapore |
| 16:45 - 16:55 |
Lamivudine Plus Adefovir or Entecavir for Patients with Chronic Hepatitis B Resistant to Lamivudine and Adefovir
Young-Suk Lim, Seoul |
| 16:55 - 17:05 |
Entecavir Five-year Resistance Data in Nucleoside-Naïve 66 fixed Japanese Patients
Masao Omata, Yamanashi |
| 17:05 - 17:15 |
Prolonged Efficacy and Safety of 4 Years Continuous Telbivudine Treatment in Chronic Hepatitis B (CHB) Patients from Globe and 015 Studies
Ji-Dong , East Hanover |
| 17:15 - 17:25 |
Treatment of Hepatitis B e Antigen-positive Chronic Hepatitis B Infection with Peginterferon Alfa-2a [40KD] (PEGASYS) Plus Lamivudine or Adefovir for 96 Weeks Results in High Rates of HBsAg Clearance/Seroconversion
Xinyue Chen, Westerham |
| 17:25 - 17:35 |
A Pilot Study of Interferon Alpha/Peginterferon Alfa-2a Combined with Response-guided Short-term Nucleoside Analog Therapy in HBeAg-positive Hepatitis B Patients
Huang Zhanlian, Westerham |
| 17:35 - 17:45 |
Identification of a Baseline Algorithm that Predicts Maximal Likelihood of HBeAg Seroconversion 6 Months Post-treatment with Peginterferon Alfa-2a (40KD) (PEGASYS)
T Piratvisuth, Westerham |
| 17:45 - 17:55 |
A Study of the Efficacy and Safety of Telbivudine in Pregnancy for the Prevention of Perinatal Transmission of Hepatitis B Virus Infection
Guo-rong Han, Nanjing |
| 17:55 - 18:05 |
A Three-years Study on Viral Suppression and Resistance Profile for Treatment Naive CHB Patients Receiving Continuous Entecavir Treatment
Wai Kay Seto, Hong Kong |
| 18:05 - 18:15 |
Ten Year Outcomes of Lamivudine Treatment in Chronic Hepatitis B (CHB) Patients with Advanced Liver Disease
Bei Xu, Shanghai |
|
| 16:15 - 18:15 |
: |
Free Paper Presentation 9: Hepatitis C (I)
| Venue: |
Meeting Room 403 |
| 16:15 - 16:25 |
Liver Stiffness and Duration of Infection in Patients with Transfusion-transmitted Chronic Hepatitis C
Ryota Masuzaki, Tokyo |
| 16:25 - 16:35 |
Predicting Treatment Response in Hepatitis C Virus Infected Patients: From Gene to Protein Expression
Limin Chen, Toronto |
| 16:35 - 16:45 |
Serum ALT Levels and HCV Viraemia Effect the Complications in Neonates Born from HCV Infected Mothers
Liang Chen, Shanghai |
| 16:45 - 16:55 |
An Optimal Duration of Treatment for Chronic Hepatiitis C Genotype 1 Patients
Thu Thuy Pham, Ho Chi Minh City |
| 16:55 - 17:05 |
Efficacy and Safety of Telaprevir-based Regimen and 1-year Durability of SVR in PROVE3 Study of Hepatitis C Genotype 1-infected Patients Who have not Responded to Prior Peginterferon-Alfa-2a/b and Ribavirin Therapy
Michael P Manns, Hackensack |
| 17:05 - 17:15 |
Selecting Patients for Abbreviated Treatment (16 Weeks) with Peginterferon Alfa-2a (40KD) Plus Ribavirin for Patients Infected with HCV Genotype 2/3
Maribel Rodriguez-Torres, Puerto Rico |
| 17:15 - 17:25 |
Simulating the Decline of HCV Infected Hepatocytes by Mathematical Modelling Allows for Individual Tailoring of Peg-IFN+RBV Therapy with Significant Savings
Piero Colombatto, Pisa |
| 17:25 - 17:35 |
Negative Predictors Affecting Early (EVR) and Sustained (SVR) Virological Response in Chronic Hepatitis C Treated with Peginterferon Plus Ribavirin
Eugen Georgescu, Craiova |
| 17:35 - 17:45 |
Telaprevir Q8h or Q12h Combined with either Peginterferon (PEG-IFN, P) Alfa-2a or Alfa-2b and Ribavirin (RBV, R) in Treatment-naïve Genotype 1 Hepatitis C Patients: Final Results of the Randomized, Open-label, Multicenter Phase 2 Study C208
Patrick Marcellin, Clichy |
| 17:45 - 17:55 |
Prospective Comparison of FibroTest and FibroScan to Predict Moderate–severe-stage Fibrosis in Asian Patients with Chronic Hepatitis C
K Patel, New York |
| 17:55 - 18:05 |
Insulin Resistance was Independently Associated with Significant Hepatic Fibrosis in Asian Patients with Chronic Hepatitis C: Analysis of the Achieve 2/3 Cohort
A Thompson, New York |
| 18:05 - 18:15 |
IL-28B SNPs and HCV Genetic Profiles, NS5A-ISDR and Core Mutations are Significant Predictors of PEG-interferon Plus Ribavirin Treatment Outcomes
Naoya Sakamoto, Tokyo |
|
| 16:15 - 18:15 |
: |
Free Paper Presentation 10: Hepatocellular Carcinoma (I)
| Venue: |
Meeting Room 405 |
| 16:15 - 16:25 |
Giant Symptomatic Hepatic Cavernous Hemangiomas are Effectively Treated by Percutaneous Ultrasonography-guided Radiofrequency Ablation
Soo Young Park, Daegu |
| 16:25 - 16:35 |
Expression and Clinical Values of IGFII-mRNA in Patients with Hepatocellular Carcinoma
Dengfu Yao, New York |
| 16:35 - 16:45 |
Efficacy and Safety of Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC): Subgroup Analyses of the Asia Pacific (AP) Trial by Baseline Transaminase (ALT/AST)/ Alpha Fetoprotein (AFP) and Bilirubin Levels
Zhendong Chen, New York |
| 16:45 - 16:55 |
Implication of Serum Nerve Growth Factor in Patient with Hepatocellular Carcinoma
Dean Tian, Wuhan |
| 16:55 - 17:05 |
Cloning and Functional Study of Novel Genes and their Predicting Value for HCC
Jie Liu, Shanghai |
| 17:05 - 17:15 |
The BCLC System Provides the Best Discrimination Ability for Overall Survival of Untreated Hepatocellular Carcinoma Patients
Jeong-Hoon Lee, Seoul |
| 17:15 - 17:25 |
Prevalence of Metabolic Abnormalities and its Association with HCC in Patients with HBV Infection
Jin-Yan Zhao, Shanghai |
| 17:25 - 17:35 |
Glutamine Synthetase: a Novel Serum Marker for Early Hepatocellular Carcinoma — Proteomic Analysis of Small Hepatocellular Carcinoma
Long Jiang, Beijing |
| 17:35 - 17:45 |
Prognosis Difference for Hepatocellular Carcinoma with Negative or Elevated Serum AFP Treated with Transcatheter Arterial Chemoembolizaion
Zhenggang Ren, Shanghai |
| 17:45 - 17:55 |
Clinical Characteristics and Prognosis of Hepatocellular Carcinoma with Lower Serum Values of Both AFP and PIVKA-II
Myoung Ha Lee, Seoul |
| 17:55 - 18:05 |
Magnetic Resonace Cholangiography is Superior to Endoscopic Retrograde Cholangiography for Accurate Diagnosis of Oriental Cholangio Hepatitis
Gul Javid, Srinagar |
| 18:05 - 18:15 |
Improving Detection of Liver Metastases Compared with Enhanced CT or SPIO-MRI: Contrast-enhanced Urtrasonography Using Sonazoid
Shinpei Sato, Tokyo |
|
| 16:15 - 18:15 |
: |
Free Paper Presentation 11: Liver Fibrosis (II)
| Venue: |
Meeting Room 406 |
| 16:15 - 16:25 |
Transdifferentiation Dependent Inhibition of TGF-beta / Smad2/3 Signaling in Rat Hepatic Stellate Cells by 1,7-Dimethylxanthine
Olav A Gressner, Aachen |
| 16:25 - 16:35 |
Study of Contractile Mechanism of Rat Hepatic Stellate Cells Induced by Endothelin-1
Lieming Xu, Shanghai |
| 16:35 - 16:45 |
microRNA-16 in Proliferation, Activation, and Apoptosis in Rat Hepatic Stellate Cells
Canjie Guo, Shanghai |
| 16:45 - 16:55 |
NIM811 Attenuates CCl4 Induced Liver Fibrosis in Rats
Hui Wang, Beijing |
| 16:55 - 17:05 |
Interleukin-17 Involved in Liver Fibrosis Induced by Carbon Tetrachloride Injection and Bile Duct Ligation
Fanli Meng, Jinan |
| 17:05 - 17:15 |
Kupffer Cells and Sinusoidal Endothelial Cells Mediate the Anti-fibrogenic Effects of Adiponectin on Hepatic Stellate Cells
Yingdi Liu, Sydney |
| 17:15 - 17:25 |
Effect of Blueberry on Hepatic and Immunological Functions in Mice
Yu-Ping Wang, Beijing |
| 17:25 - 17:35 |
A Novel Pirfenidone Analogue F351 Inhibits Experimental Liver Fibrosis in Rodents by Downregulating Transforming Growth Factor β1 (TGF-β1) and Collagen I mRNA Expression
Xin-yan Zhao, Beijing |
| 17:35 - 17:45 |
Galectin-3 Mediates Liver Fibrogenesis by Inducing Hepatic Stellate Cell Phagocytosis in Vivo
Joy X. Jiang, Sacramento |
| 17:45 - 17:55 |
The Role of the Hepatocyte and CD147 in Chronic Liver Injury
Nicholas Shackel, Newtown |
| 17:55 - 18:05 |
(+)-Episesamin from Lindera Obtusiloba Counteracts Liver Fibrosis by Abrogating TGF-β Induced Gene Expression in Hepatic Stellate Cells
Martin Ruehl, Berlin |
| 18:05 - 18:15 |
miR29 Targets the Potent Angiogenic and Mitogenic Growth Factors IGF-I as well as Two Members of the VEGF/PDGF Family
Monika Kwiecinski, Cologne |
|